CAH at a glance
Cardinal Health (CAH, SEC CIK 721371) filed its latest 10-K annual report on August 11, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended June 30, 2026 (FY2026), Cardinal Health (CAH) reported revenue of $254.2 billion (up 14.2% from FY2025) and net income of $1.7 billion. Diluted EPS was $7.23.
- As of September 30, 2026, 49 institutional investment managers tracked by SignalX reported holding Cardinal Health (CAH) shares worth $22.5 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $254.2B
- +14.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 49 funds
- $22.5B · −2 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 5.07
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $254.2B, up 14% YoY; Pharma segment up 15% to $234.8B, GMPD flat at $12.7B, Other +26% to $6.8B
- Operating margin approx. 1.03% ($2.613B / $254.2B) GAAP operating earnings up 15%, Non-GAAP margin 1.43% ($3.624B), Non-GAAP operating earnings up 30%
- Best segment: Pharma profit $2.783B up 23%; Worst: GMPD profit $258M up 91% but lowest dollar profit among segments
- Cash flow: Operating cash flow $5.2B; Capex $649M; Dividends $491M; Share repurchases $1.4B; Solaris Health acquisition $1.9B; New long-term debt net $1B; Cash and equivalents $4.9B
- Forward outlook: Management warns of tariff-related risks, regulatory uncertainties on branded pharma pricing, moderating GLP-1 demand, expects FY27 capex ~$700M, new $5B share repurchase program authorized
Risk Factors
- DOJ Civil Investigative Demand November 2023 for potential Anti-Kickback Statute and False Claims Act violations in 2022 acquisition
- $200M IEEPA tariffs paid on GMPD segment goods with $200M receivable recorded in Q4 FY26 for expected U.S. Government refund
- FDA April 2024 warning letter on plastic syringes from Chinese manufacturer lacking 510(k) clearance, requiring corrective actions
- Competitive pressure from healthcare industry consolidation risking customer loss due to greater negotiating power of combined enterprises
- IRS tax audit challenging CARES Act self-insurance losses risking $400M additional tax expense plus $1.4B liability for 2015-2020 fiscal years
AI summary of the CAH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Risk Factors
- No risk-factor text provided; only filing index and signatures included
AI summary of the CAH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.07: Submission of Matters to a Vote of Security Holders
- All 11 director nominees reelected for one-year terms, with votes supporting each nominee exceeding 176 million
- Say-on-pay approved on an advisory basis, with 173,487,665 votes for and 8,501,886 against
Item 2.02: Results of Operations and Financial Condition
- Cardinal Health announced fiscal Q1 2026 results for the quarter ended September 30, 2026
- Detailed financial results and management commentary are contained in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Webcast covers quarter ended September 30, 2026 results and fiscal 2027 outlook
- CEO and CFO presentation scheduled for November 5, 2026 at 8:30 a.m. Eastern time
Item EX-99.1: Item EX-99.1
- Q1 FY27 revenue $67.5B, up 5%; non-GAAP EPS $3.26, up 28%, signaling strong operating momentum
- Pharmaceutical and Specialty Solutions profit $783M, up 17%, while GMPD profit fell 28% to $33M
Item 7.01: Regulation FD Disclosure
- Binding letter of intent extends pharmaceutical distribution agreements with CVS Health through June 2032
- Long-duration CVS relationship provides visibility into Cardinal Health’s distribution revenue
AI summaries of CAH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CAH
Don't miss the next CAH filing
- Alerts as it files. A push when CAH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CAH, by share count.
- Ask anything. An AI agent that reads every CAH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Killefer Nancy | A | Nov 12, 2026 | 755 | - |
| Ramakrishna Sudhakar | A | Nov 12, 2026 | 755 | - |
| Evans David C | A | Nov 12, 2026 | 755 | - |
| Musslewhite Robert W | A | Nov 12, 2026 | 755 | - |
| Azelby Robert | A | Nov 12, 2026 | 755 | - |
| Hall Patricia Hemingway | A | Nov 12, 2026 | 1,204 | - |
| Brennan Michelle | A | Nov 12, 2026 | 755 | - |
| Edison Sheri H. | A | Nov 12, 2026 | 755 | - |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $222.6B | $254.2B |
| Gross Profit | - | $8.2B | $9.8B |
| Operating Income | - | $2.3B | $2.6B |
| Net Income | - | $1.6B | $1.7B |
| Gross Margin | - | 3.7% | 3.8% |
| Op. Margin | - | 1.0% | 1.0% |
| Net Margin | - | 0.7% | 0.7% |
| Balance Sheet | |||
| Total Assets | $45.1B | $53.1B | $57.3B |
| Equity | - | -$2.8B | -$2.9B |
| ROE | - | -56.1% | -59.5% |
| Per Share | |||
| EPS | - | $6.45 | $7.23 |
| Cash Flow | |||
| Operating CF | - | $2.4B | $5.2B |
| CapEx | $511.0M | $547.0M | $649.0M |
Source: XBRL data in Cardinal Health (CAH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CAH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 49 | $22.47B |
| Q2 2026 | 51 | $24.45B |
| Q1 2026 | 48 | $22.85B |
| Q4 2025 | 48 | $22.71B |
| Q3 2025 | 50 | $18.67B |
| Q2 2025 | 47 | $19.43B |
| Q1 2025 | 44 | $11.65B |
| Q4 2024 | 41 | $8.97B |
- JPMorgan Chase & Co+512.7K (+19%)
- Morgan Stanley+472.1K (+10%)
- Millennium Management+439.7K (+173%)
- Ameriprise Financial+412.8K (+31%)
- D.E. Shaw & Co+322.5K (+59%)
- BlackRock−918.9K (-3%)
- T. Rowe Price Group−802.4K (-36%)
- Northern Trust−296.9K (-10%)
- Vanguard Portfolio Management LLC−173.7K (-1%)
- Wells Fargo & Co−150.3K (-16%)
- Marex Group plc+1.8K
- FMR LLC (Fidelity)−2.07M
- Equitable Holdings Inc−13.6K
- Two Sigma Investments−1.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 378 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CAH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | - | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
Related Health Care companies
- COR · CencoraWholesale-Drugs, Proprietaries & Druggists' Sundries
- HLF · HERBALIFE LTD.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- MCK · McKesson CorporationWholesale-Drugs, Proprietaries & Druggists' Sundries
- NUS · NU SKIN ENTERPRISES, INC.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
CAH SEC filings: frequently asked questions
Which institutions hold CAH stock?
As of September 30, 2026, the largest Cardinal Health (CAH) holders among the 13F filers tracked by SignalX were BlackRock ($5.7 billion), Vanguard Capital Management LLC ($3.4 billion), Vanguard Portfolio Management LLC ($3.0 billion), State Street Corp ($2.7 billion), Morgan Stanley ($1.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CAH's revenue in fiscal year 2026?
For the fiscal year ended June 30, 2026 (FY2026), Cardinal Health (CAH) reported revenue of $254.2 billion (up 14.2% from FY2025) and net income of $1.7 billion. Diluted EPS was $7.23. The figures come from the XBRL data in the 10-K.
What are the main risks in CAH's latest 10-K?
In the 10-K filed August 11, 2026, Cardinal Health (CAH) flagged: DOJ Civil Investigative Demand November 2023 for potential Anti-Kickback Statute and False Claims Act violations in 2022 acquisition. $200M IEEPA tariffs paid on GMPD segment goods with $200M receivable recorded in Q4 FY26 for expected U.S. Government refund. (AI summary of the Risk Factors section.)
What did CAH report in its latest 8-K?
Cardinal Health (CAH) filed an 8-K on November 16, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). All 11 director nominees reelected for one-year terms, with votes supporting each nominee exceeding 176 million.
What are the latest CAH SEC filings?
Cardinal Health (CAH) filed its latest 10-K annual report on August 11, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 16, 2026.
What is CAH's SEC CIK number?
Cardinal Health (CAH)'s SEC Central Index Key (CIK) is 721371. EDGAR lists every CAH filing under that number.
Ask anything about CAH
The research agent reads CAH's filings, financials, insider trades and 13F holders, then answers with sources.